Bruker Gestion
Gestion contrôle des critères 4/4
Le PDG Bruker est Frank Laukien, nommé en Feb1991, a un mandat de 35.25 ans. La rémunération annuelle totale est $ 4.71M, composée du salaire de 20.7% et des bonus 79.3%, y compris les actions et options de la société. détient directement 26.54% des actions de la société, d'une valeur de $ 1.72B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 13.3 ans et 10.3 ans.
Informations clés
Frank Laukien
Directeur général
US$4.7m
Rémunération totale
| Pourcentage du salaire du PDG | 20.75% |
| Durée du mandat du directeur général | 35.3yrs |
| Propriété du PDG | 26.5% |
| Durée moyenne d'occupation des postes de direction | 13.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 10.3yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • May 14
BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds
Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.
Mise à jour du récit • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.Mise à jour du récit • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.Mise à jour du récit • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Seeking Alpha • Mar 31
Bruker: A Better, Yet Speculative Proposition
Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking AlphaMise à jour du récit • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.Mise à jour du récit • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.Mise à jour du récit • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Article d’analyse • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...Mise à jour du récit • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.Mise à jour du récit • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.Mise à jour du récit • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.Mise à jour du récit • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.Mise à jour du récit • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Article d’analyse • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...Mise à jour du récit • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.Mise à jour du récit • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Article d’analyse • Aug 10
Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...Mise à jour du récit • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Article d’analyse • Jun 25
Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price
Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...Article d’analyse • May 31
A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$36m |
| Dec 31 2025 | US$5m | US$977k | -US$22m |
| Sep 30 2025 | n/a | n/a | -US$24m |
| Jun 30 2025 | n/a | n/a | US$80m |
| Mar 31 2025 | n/a | n/a | US$80m |
| Dec 31 2024 | US$6m | US$966k | US$113m |
| Sep 30 2024 | n/a | n/a | US$305m |
| Jun 30 2024 | n/a | n/a | US$352m |
| Mar 31 2024 | n/a | n/a | US$402m |
| Dec 31 2023 | US$6m | US$926k | US$427m |
| Sep 30 2023 | n/a | n/a | US$319m |
| Jun 30 2023 | n/a | n/a | US$319m |
| Mar 31 2023 | n/a | n/a | US$312m |
| Dec 31 2022 | US$5m | US$873k | US$297m |
| Sep 30 2022 | n/a | n/a | US$275m |
| Jun 30 2022 | n/a | n/a | US$274m |
| Mar 31 2022 | n/a | n/a | US$282m |
| Dec 31 2021 | US$6m | US$812k | US$277m |
| Sep 30 2021 | n/a | n/a | US$270m |
| Jun 30 2021 | n/a | n/a | US$238m |
| Mar 31 2021 | n/a | n/a | US$204m |
| Dec 31 2020 | US$4m | US$689k | US$158m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$165m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$753k | US$197m |
Rémunération vs marché: La rémunération totale de Frank ($USD 4.71M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 8.47M ).
Rémunération et revenus: La rémunération de Frank a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Frank Laukien (65 yo)
35.3yrs
Titularisation
US$4,706,388
Compensation
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation since February 1991. Dr. Laukien serves as the Chairman, Chief Executive Officer and Preside...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 35.3yrs | US$4.71m | 26.54% $ 1.7b | |
| Executive VP & CFO | 8.2yrs | US$2.01m | 0.037% $ 2.4m | |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | 13.7yrs | US$2.18m | 0.055% $ 3.6m | |
| President of Bruker CALID Group & Bruker Daltonics Division | 13.3yrs | US$1.42m | 0.090% $ 5.9m | |
| President of Bruker BioSpin Group | 8yrs | US$1.42m | 0.020% $ 1.3m | |
| Chief Accounting Officer | 1.3yrs | pas de données | 0.00064% $ 41.5k | |
| Senior VP | no data | pas de données | pas de données | |
| President and CEO of Bruker Energy & Supercon Technologies | 18.1yrs | US$967.91k | 0.010% $ 680.1k |
13.3yrs
Durée moyenne de l'emploi
60.5yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de BRKR est chevronnée et expérimentée (13.3 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 35.3yrs | US$4.71m | 26.54% $ 1.7b | |
| Independent Director | 10.8yrs | US$272.53k | 0.023% $ 1.5m | |
| Independent Director | 10.5yrs | US$260.20k | 0.023% $ 1.5m | |
| Lead Director | 19yrs | US$263.37k | 0.059% $ 3.8m | |
| Independent Director | 26.3yrs | US$252.95k | 0.039% $ 2.5m | |
| Independent Director | 1.3yrs | US$243.35k | pas de données | |
| Independent Director | 9yrs | US$252.03k | 0.016% $ 1.0m | |
| Independent Director | less than a year | pas de données | pas de données | |
| Independent Director | 10.8yrs | US$247.62k | 0.017% $ 1.1m | |
| Independent Director | 5.7yrs | US$258.45k | 0.0088% $ 567.3k | |
| Independent Director | less than a year | pas de données | 0% $ 0 | |
| Independent Director | 10yrs | US$247.62k | 0.012% $ 767.6k |
10.3yrs
Durée moyenne de l'emploi
67yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la BRKR est chevronné et expérimenté ( 10.3 années d'ancienneté moyenne).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 07:18 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bruker Corporation est couverte par 29 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |